Lechapt‐Zalcman 2012.

Study characteristics
Study design	Cohort
Study setting	Setting: network of 11 neurosurgical university departments Country: France Dates: tumour samples collected between 2005 and 2009
Selection of participants	Tumour samples collected from 2 observational studies analysing the use of Gliadel implants in people with newly diagnosed GBM
Participant characteristics	Sample size: 111 (deaths: 56) Age: median 58, SD NR; range 33–77 years Sex: 65.8% men KPS: mean 80.2, SD 13.5
Tumour characteristics	GBM: 100% First diagnosis: 100% Biopsy: 0%; subtotal resection: 30%; total resection: 55.5%; total 100% disappearance of contrast enhancement, subtotal ≥ 90% disappearance of contrast enhancement, partial < 90% disappearance of contrast enhancement. IDH1 wild‐type: NR; IDH2 wild‐type: NR
Treatment regimen	Gliadel (carmustine) wafers followed by the Stupp protocol
MGMT promoter methylation tests implemented	MSP, PSQ
Dates and follow‐up	Timing of MGMT assessment: at diagnosis Start time for follow‐up: NR; follow‐up: median 13.6; range 0–37.6 months
Notes